Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$250.6(0.2%)
Market Cap$32.2B
LTM Free Cash Flow
($42.6M)
Reverse DCF (Implied FCF growth)
(100.0%)
3Y Free Cash Flow CAGR
(61.0%)
LTM Revenue
$2,248.2M
Reverse DCF (Implied Revenue growth)
38.0%
at normalized FCF margin 4.2%
3Y Revenue CAGR
38.6%
ALNY Reverse DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
ALNY Free Cash Flow
Crunching data... Almost there!
ALNY Growth
Crunching data... Almost there!
ALNY vs Peer Set: Reverse DCF comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for ALNY
DCF value calculator
Peter Lynch Fair Value
Discount rate
Relative Value
Earnings growth model
Peter Lynch charts
Margin of safety
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
FAQ
What is Alnylam Pharmaceuticals, Inc. Reverse DCF (discounted cash flow) valuation?
As of Dec 31, 2024, Alnylam Pharmaceuticals, Inc.'s Reverse Discounted Cash Flow (DCF) valuation estimates its Free Cash Flow growth at (100.0%).
What is Alnylam Pharmaceuticals, Inc. WACC?
As of Dec 31, 2024, Alnylam Pharmaceuticals, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 7.6%.
What is Alnylam Pharmaceuticals, Inc. Free Cash Flow?
As of Dec 31, 2024, Alnylam Pharmaceuticals, Inc.'s Free Cash Flow is ($42.6M).